Evidence map›Paper›PMID 39598343›Full record

ArticlePharmaceuticals (Basel, Switzerland)2024

Efficacy and Safety of Rivaroxaban, Apixaban, and Edoxaban for Nonvalvular Atrial Fibrillation Based on Blood Coagulation Activity and Drug Plasma Concentration: SETtsu and North Osaka Multicenter Direct Oral AntiCoagulant (SET DOAC) Registry.

Michihiro Suwa, Isao Morii, Masaya Kino, Yumie Matsui, Masahiro Yoshinaga, Hiroki Takahashi, Masahiko Takagi, Akira Yoshida, Minoru Ichikawa, Osamu Nakajima and 6 more

Abstract read
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. A FABulous approach to image human macrophages.European journal of nuclear medicine and molecular imaging · 2026
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Michihiro SuwaDepartment of Cardiology, Hokusetsu General Hospital, Osaka 569-8585, Japan.ORCID 0000-0003-0177-326X
Isao MoriiDepartment of Cardiology, Hokusetsu General Hospital, Osaka 569-8585, Japan.
Masaya KinoDepartment of Cardiology, Hokusetsu General Hospital, Osaka 569-8585, Japan.
Yumie MatsuiDepartment of Cardiology, Saiseikai Izuo Hospital, Osaka 551-0032, Japan.
Masahiro YoshinagaDepartment of Cardiology, Saiseikai Izuo Hospital, Osaka 551-0032, Japan.
Hiroki TakahashiDepartment of Cardiology, Kansai Medical University Medical Center, Moriguchi 570-8507, Japan.
Masahiko TakagiDepartment of Cardiology, Kansai Medical University Medical Center, Moriguchi 570-8507, Japan.
Akira YoshidaDepartment of Cardiology, Higashiosaka Municipal Hospital, Higashiosaka, 578-8588, Japan.
Minoru IchikawaDepartment of Cardiology, Higashiosaka Municipal Hospital, Higashiosaka, 578-8588, Japan.ORCID 0000-0003-0110-199X
Osamu NakajimaDepartment of Cardiology, Hirakata Municipal Hospital, Hirakata 573-1013, Japan.
Mitsuhiro TanimuraMidorigaoka Hospital, Takatsuki 569-1121, Japan.
Hisashi ShimoyamaItami City Hospital, Itami 664-8540, Japan.
Hiroyuki SaitohDepartment of Cardiology, Yukoukai General Hospital, Ibaraki 567-0058, Japan.
Isao SasakiAinomiyako Neurosurgery Hospital, Osaka 538-0044, Japan.
Takeshi SuzukiSysmex Corporation, Kobe 651-2241, Japan.
Satoshi UemaeSysmex Corporation, Kobe 651-2241, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

anticoagulation monitoringapixabanatrial fibrillationedoxabanon-label dosingrivaroxaban

Identifiers

PMID39598343
PMCPMC11597286

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.